Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1087301

Bio-Naive Crohn's Disease Patients with Long- Standing Disease Benefit from Ustekinumab Treatment: Real World Experience


Tomašić, Vedran; Drobne, David; Borzan, Vladimir; Bišćanin, Alen; Hanžel, Jurij; Oršić Frič, Vlasta; Ćaćić, Petra; Štabuc, Borut; Ogresta, Doris; Kralj, Dominik et al.
Bio-Naive Crohn's Disease Patients with Long- Standing Disease Benefit from Ustekinumab Treatment: Real World Experience // Ueg Journal 8(S8)
Online, 2020. str. 330-330 doi:10.1177/2050640620927345 (poster, međunarodna recenzija, sažetak, ostalo)


CROSBI ID: 1087301 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Bio-Naive Crohn's Disease Patients with Long- Standing Disease Benefit from Ustekinumab Treatment: Real World Experience

Autori
Tomašić, Vedran ; Drobne, David ; Borzan, Vladimir ; Bišćanin, Alen ; Hanžel, Jurij ; Oršić Frič, Vlasta ; Ćaćić, Petra ; Štabuc, Borut ; Ogresta, Doris ; Kralj, Dominik ; Dorosulić, Zdravko ; Hrabar, Davor

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo

Izvornik
Ueg Journal 8(S8) / - , 2020, 330-330

Skup
28th United European Gastroenterology Week Virtual 2020

Mjesto i datum
Online, 11-13.10.2020

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
ustekinumab, Crohn disease

Sažetak
Introduction: Ustekinumab (UST) is a human anti- IL12/23 p40 monoclonal antibody, approved for treatment of Crohn’s Disease (CD). This multicenter, non-interventional, retrospective chart review explored robust real-life data in patients receiving UST to access long-term efficacy and treatment persistence of UST treatment in the bio- naive CD population with long-standing disease. Aims & Methods: Clinical data, such as maintenance of clinical response using Harvey-Bradshaw index, combined steroid-free and biochemical clinical remission, endoscopic response/healing via the simple endoscopic score for Crohn’s disease (SES-CD), dose escalation and treatment persistence were assessed in 42 adult patients (55% female ; mean age 46 ± 15.1 years ; mean BMI 25.28 ± 4.5 kg/m2 ) with long-standing (mean duration of 10, 5 years) biologic-naive CD from 3 tertiary centers (one Slovenian and two Croatian) between January 2018 and April 2020. Data were collected before first infusion, at week (W)24, W52, as well as last follow-up. Results: At W24 84% (35/42) of CD patients had achieved clinical response and 38.1% (16/42) were in combined steroid-free and biochemical clinical remission. After an average of 16 months of treatment duration, 88.1% (37/42) of CD patients were still on UST treatment, 71.4% (30/42) had maintained clinical response and 35.7% (15/42) were in sustained steroidfree clinical remission. The number of patients requiring steroid treatment was reduced by 87%. Mean HBI decreased from 8 to 3 and SES-CD from 6 to 2. The majority [59.53%] of patients started ustekinumab as monotherapy, i.e. without concomitant immunomodulator medication. 31% of patients experienced UST dose escalation. Conclusion: UST offers an effective and persistent steroid sparing treatment option in this real-life multicenter study of bio-naive CD patients with long-standing disease

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti



POVEZANOST RADA


Ustanove:
Medicinski fakultet, Zagreb,
KBC "Sestre Milosrdnice"

Profili:

Avatar Url Davor Hrabar (autor)

Avatar Url Petra Ćaćić (autor)

Avatar Url Vedran Tomašić (autor)

Avatar Url Alen Bišćanin (autor)

Poveznice na cjeloviti tekst rada:

doi journals.sagepub.com

Citiraj ovu publikaciju:

Tomašić, Vedran; Drobne, David; Borzan, Vladimir; Bišćanin, Alen; Hanžel, Jurij; Oršić Frič, Vlasta; Ćaćić, Petra; Štabuc, Borut; Ogresta, Doris; Kralj, Dominik et al.
Bio-Naive Crohn's Disease Patients with Long- Standing Disease Benefit from Ustekinumab Treatment: Real World Experience // Ueg Journal 8(S8)
Online, 2020. str. 330-330 doi:10.1177/2050640620927345 (poster, međunarodna recenzija, sažetak, ostalo)
Tomašić, V., Drobne, D., Borzan, V., Bišćanin, A., Hanžel, J., Oršić Frič, V., Ćaćić, P., Štabuc, B., Ogresta, D. & Kralj, D. (2020) Bio-Naive Crohn's Disease Patients with Long- Standing Disease Benefit from Ustekinumab Treatment: Real World Experience. U: Ueg Journal 8(S8) doi:10.1177/2050640620927345.
@article{article, author = {Toma\v{s}i\'{c}, Vedran and Drobne, David and Borzan, Vladimir and Bi\v{s}\'{c}anin, Alen and Han\v{z}el, Jurij and Or\v{s}i\'{c} Fri\v{c}, Vlasta and \'{C}a\'{c}i\'{c}, Petra and \v{S}tabuc, Borut and Ogresta, Doris and Kralj, Dominik and Dorosuli\'{c}, Zdravko and Hrabar, Davor}, year = {2020}, pages = {330-330}, DOI = {10.1177/2050640620927345}, keywords = {ustekinumab, Crohn disease}, doi = {10.1177/2050640620927345}, title = {Bio-Naive Crohn's Disease Patients with Long- Standing Disease Benefit from Ustekinumab Treatment: Real World Experience}, keyword = {ustekinumab, Crohn disease}, publisherplace = {Online} }
@article{article, author = {Toma\v{s}i\'{c}, Vedran and Drobne, David and Borzan, Vladimir and Bi\v{s}\'{c}anin, Alen and Han\v{z}el, Jurij and Or\v{s}i\'{c} Fri\v{c}, Vlasta and \'{C}a\'{c}i\'{c}, Petra and \v{S}tabuc, Borut and Ogresta, Doris and Kralj, Dominik and Dorosuli\'{c}, Zdravko and Hrabar, Davor}, year = {2020}, pages = {330-330}, DOI = {10.1177/2050640620927345}, keywords = {ustekinumab, Crohn disease}, doi = {10.1177/2050640620927345}, title = {Bio-Naive Crohn's Disease Patients with Long- Standing Disease Benefit from Ustekinumab Treatment: Real World Experience}, keyword = {ustekinumab, Crohn disease}, publisherplace = {Online} }

Časopis indeksira:


  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font